Bill Anderson, Roche Pharmaceuticals CEO (Photographer: David Paul Morris, via Getty Images)
August 16, 2022 10:23 AM EDTUpdated 02:06 PM
R&D
Pharma

Roche’s Po­livy con­tin­ues its reg­u­la­to­ry dance, will head to FDA for a form of blood can­cer

Tyler Patchen

News Reporter

While Roche has pre­vi­ous­ly tout­ed Po­livy da­ta for dif­fuse large B-cell lym­phoma (DL­B­CL), the drug has faced some de­lays on the reg­u­la­to­ry side. But the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times